247 related articles for article (PubMed ID: 30564580)
1. Recombinant Heparin-New Opportunities.
Glass CA
Front Med (Lausanne); 2018; 5():341. PubMed ID: 30564580
[TBL] [Abstract][Full Text] [Related]
2. Design of biologically active heparan sulfate and heparin using an enzyme-based approach.
Peterson S; Frick A; Liu J
Nat Prod Rep; 2009 May; 26(5):610-27. PubMed ID: 19387498
[TBL] [Abstract][Full Text] [Related]
3. Metabolic engineering of mammalian cells to produce heparan sulfates.
Thacker BE; Sharfstein ST
Emerg Top Life Sci; 2018 Oct; 2(3):443-452. PubMed ID: 33525792
[TBL] [Abstract][Full Text] [Related]
4. Antibody-based assay for N-deacetylase activity of heparan sulfate/heparin N-deacetylase/N-sulfotransferase (NDST): novel characteristics of NDST-1 and -2.
van den Born J; Pikas DS; Pisa BJ; Eriksson I; Kjellen L; Berden JH
Glycobiology; 2003 Jan; 13(1):1-10. PubMed ID: 12634318
[TBL] [Abstract][Full Text] [Related]
5. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor.
Vlodavsky I; Miao HQ; Medalion B; Danagher P; Ron D
Cancer Metastasis Rev; 1996 Jun; 15(2):177-86. PubMed ID: 8842489
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic synthesis of heparan sulfate and heparin.
Joice A; Raman K; Mencio C; Quintero MV; Brown S; Nguyen TK; Kuberan B
Methods Mol Biol; 2015; 1229():11-9. PubMed ID: 25325939
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the biological functions of heparan sulfate using a chemoenzymatic synthetic approach.
Wang Z; Arnold K; Dhurandhare VM; Xu Y; Liu J
RSC Chem Biol; 2021 Feb; 2(3):702-712. PubMed ID: 34179782
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of binding sites at the hydrophilic domain of cell-surface sulfatase Sulf1 allows for dynamic interaction of the enzyme with its substrate heparan sulfate.
Milz F; Harder A; Neuhaus P; Breitkreuz-Korff O; Walhorn V; Lübke T; Anselmetti D; Dierks T
Biochim Biophys Acta; 2013 Nov; 1830(11):5287-98. PubMed ID: 23891937
[TBL] [Abstract][Full Text] [Related]
9. Toward a bioengineered heparin: challenges and strategies for metabolic engineering of mammalian cells.
Baik JY; Wang CL; Yang B; Linhardt RJ; Sharfstein S
Bioengineered; 2012; 3(4):227-31. PubMed ID: 22714556
[TBL] [Abstract][Full Text] [Related]
10. Dissecting structure-function of 3-O-sulfated heparin and engineered heparan sulfates.
Karlsson R; Chopra P; Joshi A; Yang Z; Vakhrushev SY; Clausen TM; Painter CD; Szekeres GP; Chen YH; Sandoval DR; Hansen L; Esko JD; Pagel K; Dyer DP; Turnbull JE; Clausen H; Boons GJ; Miller RL
Sci Adv; 2021 Dec; 7(52):eabl6026. PubMed ID: 34936441
[TBL] [Abstract][Full Text] [Related]
11. The binding of the bone morphogenetic protein antagonist gremlin to kidney heparan sulfate: Such binding is not essential for BMP antagonism.
Tatsinkam AJ; Rune N; Smith J; Norman JT; Mulloy B; Rider CC
Int J Biochem Cell Biol; 2017 Feb; 83():39-46. PubMed ID: 27979781
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate and heparin interactions with proteins.
Meneghetti MC; Hughes AJ; Rudd TR; Nader HB; Powell AK; Yates EA; Lima MA
J R Soc Interface; 2015 Sep; 12(110):0589. PubMed ID: 26289657
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant heparan sulfate: structural specificity and biosynthesis.
Liu J; Pedersen LC
Appl Microbiol Biotechnol; 2007 Feb; 74(2):263-72. PubMed ID: 17131147
[TBL] [Abstract][Full Text] [Related]
14. Isolation and Characterization of a Chinese Hamster Ovary Heparan Sulfate Cell Mutant Defective in Both Met Receptor Binding and Hepatocyte Growth Factor NK1/Met Signaling.
Cao T; Pan J; Li X; He Y; Jiang Y; Chang Y; Zhang Q; Lan Y; Wang H; Jiao W; Tian Z; Zhang L
Cell Physiol Biochem; 2018; 48(4):1480-1491. PubMed ID: 30107380
[TBL] [Abstract][Full Text] [Related]
15. Identification of heparin-binding amino acid residues in antibody HS4C3 with the potential to design antibodies against heparan sulfate domains.
Damen LAA; Bui TP; Wessel T; Li Y; Straten BF; Pampiermole R; Daamen WF; Fernig DG; Kuppevelt TH
Glycobiology; 2024 Jul; ():. PubMed ID: 38963938
[TBL] [Abstract][Full Text] [Related]
16. Chemoenzymatic synthesis of heparan sulfate and heparin oligosaccharides and NMR analysis: paving the way to a diverse library for glycobiologists.
Zhang X; Pagadala V; Jester HM; Lim AM; Pham TQ; Goulas AMP; Liu J; Linhardt RJ
Chem Sci; 2017 Dec; 8(12):7932-7940. PubMed ID: 29568440
[TBL] [Abstract][Full Text] [Related]
17. Use of biosynthetic enzymes in heparin and heparan sulfate synthesis.
Chappell EP; Liu J
Bioorg Med Chem; 2013 Aug; 21(16):4786-92. PubMed ID: 23313092
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes.
Shibata S; Sasaki T; Harpel P; Fillit H
Clin Immunol Immunopathol; 1994 Feb; 70(2):114-23. PubMed ID: 8299226
[TBL] [Abstract][Full Text] [Related]
19. Mapping critical biological motifs and biosynthetic pathways of heparan sulfate.
Lawrence R; Kuberan B; Lech M; Beeler DL; Rosenberg RD
Glycobiology; 2004 May; 14(5):467-79. PubMed ID: 15033939
[TBL] [Abstract][Full Text] [Related]
20. Differences in sulfation patterns of heparan sulfate derived from human bone marrow and umbilical vein endothelial cells.
Netelenbos T; Dräger AM; van het Hof B; Kessler FL; Delouis C; Huijgens PC; van den Born J; van Dijk W
Exp Hematol; 2001 Jul; 29(7):884-93. PubMed ID: 11438211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
